-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

SVB Leerink Maintains Outperform on AbCellera Biologics, Lowers Price Target to $18

Benzinga · 01/06/2023 09:07
SVB Leerink analyst Puneet Souda maintains AbCellera Biologics (NASDAQ:ABCL) with a Outperform and lowers the price target from $20 to $18.